Stock Quote

Immunic, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn’s disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. Immunic’s lead development program, IMU-838, is in phase 2 clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional phase 2 trial in Crohn’s disease planned for 2019. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is planned to start at the Mayo Clinic.

News Releases
Apr 12, 2019

Immunic, Inc. (Nasdaq: IMUX), today announced the completion of its stock-for-stock exchange transaction with Vital Therapies, Inc. (Nasdaq: VTL, through April 12, 2019). The company has been...

Apr 10, 2019

SAN DIEGO, April 10, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc.(Nasdaq: VTL) announced that it had filed its quarterly report on Form 10-Q today. The report was filed earlier than usual to...

Apr 4, 2019

SAN DIEGO, April 04, 2019 (GLOBE NEWSWIRE) -- Vital Therapies, Inc.(Nasdaq: VTL) announced that its stockholders voted to approve the proposals required to complete the business combination with...

View More

Recent Event
Wednesday, April 10, 2019
4:10pm EDT

View More

Contact Us

Immunic, Inc.
Jessica Breu
Manager IR and Communications
+49 89 250 0794 69
jessica.breu@immunic.de

Rx Communications
Melody Carey
+1 917 322 2571
immunic@rxir.com

Fast Facts
  •  Company founded in 2016
  •  3 development programs
  •  Headquartered in the United States
  •  NASDAQ: IMUX
  •  Experts in selective oral drugs in immunology
Subscribe
To receive all investor alerts please subscribe here
* Required Fields